Follistatin-Like 1 Protects against Doxorubicin-Induced Cardiomyopathy through Upregulation of Nrf2

Doxorubicin- (DOX-) induced cardiomyocyte loss results in irreversible heart failure, which limits the clinical applications of DOX. Currently, there are no drugs that can effectively treat DOX-related cardiotoxicity. Follistatin-like 1 (FSTL1) has been reported to be a transforming growth factor-be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yintao, Sun, Jingjing, Zhang, Wei, Peng, Meng, Chen, Jun, Zheng, Lu, Zhang, Xiangqin, Yang, Haibo, Liu, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7421745/
https://www.ncbi.nlm.nih.gov/pubmed/32831995
http://dx.doi.org/10.1155/2020/3598715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7421745/
https://www.ncbi.nlm.nih.gov/pubmed/32831995
http://dx.doi.org/10.1155/2020/3598715

Ejemplares similares